L3VLUP
ProSign in

ANGO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ANGOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ANGO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterANGOJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 20211 holders, $10m31 holders, $25.3bn
Q2 20211 holders, $19m37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 20211 holders, $21m33 holders, $25.2bn
Q1 20221 holders, $25m35 holders, $28.2bn
Q2 20221 holders, $18m33 holders, $26.9bn
Q3 20221 holders, $13m36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 20231 holders, $388k42 holders, $24.5bn
Q2 20231 holders, $391k38 holders, $25.0bn
Q3 20231 holders, $6.0m37 holders, $18.9bn
Q4 20233 holders, $13m31 holders, $19.0bn
Q1 20241 holders, $5.9m32 holders, $19.7bn
Q2 20242 holders, $7.5m35 holders, $20.4bn
Q3 20241 holders, $3.1m28 holders, $22.3bn
Q4 20241 holders, $3.8m37 holders, $20.4bn
Q1 20252 holders, $4.4m32 holders, $20.5bn
Q2 20252 holders, $3.9m31 holders, $18.4bn
Q3 20253 holders, $34m32 holders, $23.7bn
Q4 20252 holders, $5.6m29 holders, $27.8bn
Q1 20262 holders, $5.4m34 holders, $35.6bn
Q2 20262 holders, $6.0m33 holders, $39.1bn
ANGO

Angiodynamics Inc

Holders
2
Reported value
$3.9m
Buyers
1
Sellers
1

Breadth 0 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ANGO (2)

First Eagle Investment Management LLC, Moore Capital Management LP

Only JNJ (31)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →